There is no established standard treatment for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in patients who are not eligible to receive an intensive treatment. The combination of rituximab gemcitabine and oxaliplatin (R-GemOx) is widely used in this population but data are scarce. We retrospectively collected the data of 196 patients with R/R DLBCL treated with R-GemOx in two French centers over a period of 15 years. The median age of the population was 72 years (range, 24-89), 63% of the patients had an international prognostic index of 3 or higher and 57% were refractory to the last treatment. At the end of R-GemOx treatment, 33% of the patients obtained a complete response. The median progression-free survival (PFS) of...
PurposeWe compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin...
Cisplatin-containing salvage regimens followed by autologous hematopoietic stem cell (HSC) transplan...
Background: We aimed to determine safety and efficacy of rituximab (R) in combination with repetitiv...
International audienceThere is no established standard treatment for relapsed/refractory (R/R) diffu...
A previous pilot study with rituximab, gemcitabine and oxaliplatin showed promising activity in pati...
PURPOSE Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation ...
PURPOSE: Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation...
Autologous stem cell transplantation (ASCT) consolidation remains the treatment of choice for patien...
Patients with relapsed-refractory diffuse large B-cell lymphoma (RR-DLBCL) ineligible for autologous...
Item does not contain fulltextAutologous stem cell transplantation (ASCT) consolidation remains the ...
Autologous stem cell transplantation (ASCT) consolidation remains the treatment of choice for patien...
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy...
Autologous stem cell transplantation (ASCT) consolidation remains the treatment of choice for patien...
Autologous stem cell transplantation (ASCT) consolidation remains the treatment of choice for patien...
Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplati...
PurposeWe compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin...
Cisplatin-containing salvage regimens followed by autologous hematopoietic stem cell (HSC) transplan...
Background: We aimed to determine safety and efficacy of rituximab (R) in combination with repetitiv...
International audienceThere is no established standard treatment for relapsed/refractory (R/R) diffu...
A previous pilot study with rituximab, gemcitabine and oxaliplatin showed promising activity in pati...
PURPOSE Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation ...
PURPOSE: Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation...
Autologous stem cell transplantation (ASCT) consolidation remains the treatment of choice for patien...
Patients with relapsed-refractory diffuse large B-cell lymphoma (RR-DLBCL) ineligible for autologous...
Item does not contain fulltextAutologous stem cell transplantation (ASCT) consolidation remains the ...
Autologous stem cell transplantation (ASCT) consolidation remains the treatment of choice for patien...
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy...
Autologous stem cell transplantation (ASCT) consolidation remains the treatment of choice for patien...
Autologous stem cell transplantation (ASCT) consolidation remains the treatment of choice for patien...
Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplati...
PurposeWe compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin...
Cisplatin-containing salvage regimens followed by autologous hematopoietic stem cell (HSC) transplan...
Background: We aimed to determine safety and efficacy of rituximab (R) in combination with repetitiv...